[
  {
    "qas": [
      {
        "answers": [
          {
            "text": "Consulting and Product Development Agreement",
            "answer_start": 0
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Document Name",
        "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "Michael T. Murray, N.D",
            "answer_start": 289
          },
          {
            "text": "Emerald Health Sciences Inc.",
            "answer_start": 203
          },
          {
            "text": "EHN",
            "answer_start": 278
          },
          {
            "text": "Emerald Health Nutraceuticals Inc.",
            "answer_start": 241
          },
          {
            "text": "Dr. Murray",
            "answer_start": 315
          },
          {
            "text": "EHS",
            "answer_start": 234
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Parties",
        "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "1st day of September 2016",
            "answer_start": 143
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Agreement Date",
        "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "1st day of September 2016",
            "answer_start": 143
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Effective Date",
        "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective\u00a0",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "Except as otherwise stated herein as pertaining only to a Services Term, this Agreement shall remain in effect for ten years, unless terminated in accordance with Sections 6.1 (a) or 6.2(b).",
            "answer_start": 6851
          },
          {
            "text": "Dr. Murray's obligations set out herein shall be performed from the Effective Date until December 31, 2018 (the initial \"Services Term\").",
            "answer_start": 6354
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Expiration Date",
        "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "The Services Term of this Agreement shall be automatically renewed for successive two-year terms thereafter unless written notice is given by either party to the other, indicating that party's intention not to renew the Services Term of this Agreement, at least ninety (90) days prior to the end of the initial Services Term or any renewed Services Term.",
            "answer_start": 6492
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Renewal Term",
        "question": "Highlight the parts (if any) of this contract related to \"Renewal Term\" that should be reviewed by a lawyer. Details: What is the renewal term after the initial term expires? This includes automatic extensions and unilateral extensions with prior notice.",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "The Services Term of this Agreement shall be automatically renewed for successive two-year terms thereafter unless written notice is given by either party to the other, indicating that party's intention not to renew the Services Term of this Agreement, at least ninety (90) days prior to the end of the initial Services Term or any renewed Services Term.",
            "answer_start": 6492
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Notice Period To Terminate Renewal",
        "question": "Highlight the parts (if any) of this contract related to \"Notice Period To Terminate Renewal\" that should be reviewed by a lawyer. Details: What is the notice period required to terminate renewal?",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Arizona without regard to conflict of law principles, may not be amended except by a writing signed by both parties, and shall supersede any and all prior discussions and writings between the parties concerning the subject matter.",
            "answer_start": 11260
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Governing Law",
        "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Most Favored Nation",
        "question": "Highlight the parts (if any) of this contract related to \"Most Favored Nation\" that should be reviewed by a lawyer. Details: Is there a clause that if a third party gets better terms on the licensing or sale of technology/goods/services described in the contract, the buyer of such technology/goods/services under the contract shall be entitled to those better terms?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "Dr. Murray shall not directly assist in the development of any product competitive to products developed by EHS or EHN.",
            "answer_start": 2279
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Non-Compete",
        "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector?\u00a0",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "EHS and EHN shall have the exclusive rights in and to all ingredients, product specifications, goodwill, and all other intellectual property rights associated with any Product(s); provided, however, that EHS and EHN shall not have any rights in or to Dr. Murray's name or likeness except as expressly granted in writing herein or via electronic transmission by Dr. Murray.",
            "answer_start": 2618
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Exclusivity",
        "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing\u00a0 commitment with the counterparty? This includes a commitment to procure all \u201crequirements\u201d from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on\u00a0 collaborating or working with other parties), whether during the contract or\u00a0 after the contract ends (or both).",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__No-Solicit Of Customers",
        "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Customers\" that should be reviewed by a lawyer. Details: Is a party restricted from contracting or soliciting customers or partners of the counterparty, whether during the contract or after the contract ends (or both)?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "EHS and EHN shall have the exclusive rights in and to all ingredients, product specifications, goodwill, and all other intellectual property rights associated with any Product(s); provided, however, that EHS and EHN shall not have any rights in or to Dr. Murray's name or likeness except as expressly granted in writing herein or via electronic transmission by Dr. Murray.",
            "answer_start": 2618
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Competitive Restriction Exception",
        "question": "Highlight the parts (if any) of this contract related to \"Competitive Restriction Exception\" that should be reviewed by a lawyer. Details: This category includes the exceptions or carveouts to Non-Compete, Exclusivity and No-Solicit of Customers above.",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__No-Solicit Of Employees",
        "question": "Highlight the parts (if any) of this contract related to \"No-Solicit Of Employees\" that should be reviewed by a lawyer. Details: Is there a restriction on a party\u2019s soliciting or hiring employees and/or contractors from the\u00a0 counterparty, whether during the contract or after the contract ends (or both)?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Non-Disparagement",
        "question": "Highlight the parts (if any) of this contract related to \"Non-Disparagement\" that should be reviewed by a lawyer. Details: Is there a requirement on a party not to disparage the counterparty?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "EHS or EHN, on the one hand, and Dr. Murray, on the other, may terminate any Services Term of this Agreement by delivering 60 days written notice to the other party.",
            "answer_start": 7296
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Termination For Convenience",
        "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate this\u00a0 contract without cause (solely by giving a notice and allowing a waiting\u00a0 period to expire)?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Rofr/Rofo/Rofn",
        "question": "Highlight the parts (if any) of this contract related to \"Rofr/Rofo/Rofn\" that should be reviewed by a lawyer. Details: Is there a clause granting one party a right of first refusal, right of first offer or right of first negotiation to purchase, license, market, or distribute equity interest, technology, assets, products or services?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Change Of Control",
        "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
        "is_impossible": true
      },
      {
        "answers": [
          {
            "text": "Dr. Murray has unique qualifications to provide the services contemplated herein, and shall not assign any of its or his rights or obligations to any other person or entity without EHS's written consent, which may be withheld or granted in EHS's discretion.",
            "answer_start": 15740
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Anti-Assignment",
        "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
        "is_impossible": false
      },
      {
        "answers": [
          {
            "text": "Dr. Murray will receive an annual royalty on net sales (defined as gross sales minus returns) for any products (the \"Dr. Murray Products\") developed by Dr. Murray for EHN for as long as the Dr. Murray Products are being sold",
            "answer_start": 3772
          }
        ],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Revenue/Profit Sharing",
        "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or\u00a0services?",
        "is_impossible": false
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Price Restrictions",
        "question": "Highlight the parts (if any) of this contract related to \"Price Restrictions\" that should be reviewed by a lawyer. Details: Is there a restriction on the\u00a0 ability of a party to raise or reduce prices of technology, goods, or\u00a0 services provided?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Minimum Commitment",
        "question": "Highlight the parts (if any) of this contract related to \"Minimum Commitment\" that should be reviewed by a lawyer. Details: Is there a minimum order size or minimum amount or units per-time period that one party must buy from the counterparty under the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Volume Restriction",
        "question": "Highlight the parts (if any) of this contract related to \"Volume Restriction\" that should be reviewed by a lawyer. Details: Is there a fee increase or consent requirement, etc. if one party\u2019s use of the product/services exceeds certain threshold?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Ip Ownership Assignment",
        "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created\u00a0 by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Joint Ip Ownership",
        "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__License Grant",
        "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Non-Transferable License",
        "question": "Highlight the parts (if any) of this contract related to \"Non-Transferable License\" that should be reviewed by a lawyer. Details: Does the contract limit the ability of a party to transfer the license being granted to a third party?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Affiliate License-Licensor",
        "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor?\u00a0",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Affiliate License-Licensee",
        "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Unlimited/All-You-Can-Eat-License",
        "question": "Highlight the parts (if any) of this contract related to \"Unlimited/All-You-Can-Eat-License\" that should be reviewed by a lawyer. Details: Is there a clause granting one party an \u201centerprise,\u201d \u201call you can eat\u201d or unlimited usage license?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Irrevocable Or Perpetual License",
        "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain a\u00a0 license grant that is irrevocable or perpetual?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Source Code Escrow",
        "question": "Highlight the parts (if any) of this contract related to \"Source Code Escrow\" that should be reviewed by a lawyer. Details: Is one party required to deposit its source code into escrow with a third party, which can be released to the counterparty upon the occurrence of certain events (bankruptcy,\u00a0 insolvency, etc.)?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Post-Termination Services",
        "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Audit Rights",
        "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to\u00a0 audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Uncapped Liability",
        "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a party\u2019s liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Cap On Liability",
        "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party\u2019s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Liquidated Damages",
        "question": "Highlight the parts (if any) of this contract related to \"Liquidated Damages\" that should be reviewed by a lawyer. Details: Does the contract contain a clause that would award either party liquidated damages for breach or a fee upon the termination of a contract (termination fee)?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Warranty Duration",
        "question": "Highlight the parts (if any) of this contract related to \"Warranty Duration\" that should be reviewed by a lawyer. Details: What is the duration of any\u00a0 warranty against defects or errors in technology, products, or services\u00a0 provided under the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Insurance",
        "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Covenant Not To Sue",
        "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty\u2019s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
        "is_impossible": true
      },
      {
        "answers": [],
        "id": "EmeraldHealthBioceuticalsInc_20200218_1-A_EX1A-6 MAT CTRCT_11987205_EX1A-6 MAT CTRCT_Development Agreement__Third Party Beneficiary",
        "question": "Highlight the parts (if any) of this contract related to \"Third Party Beneficiary\" that should be reviewed by a lawyer. Details: Is there a non-contracting party who is a beneficiary to some or all of the clauses in the contract and therefore can enforce its rights against a contracting party?",
        "is_impossible": true
      }
    ],
    "context": "Consulting and Product Development Agreement\n\nARTICLE 1 -- PREAMBLE This Consulting and Licensing Agreement (\"Agreement\") is entered into this 1st day of September 2016 (\"Effective Date\") by and between Emerald Health Sciences Inc. (\"EHS\"), Emerald Health Nutraceuticals Inc. (\"EHN\"), and Michael T. Murray, N.D. (\"Dr. Murray\"). This Agreement sets forth a description of those responsibilities of EHS, EHN, and Dr. Murray, of certain rights granted to EHS and EHN, and of certain other terms.\n\nARTICLE 2 -- RESPONSIBILITIES 2.1 EHS and EHN shall bear all costs associated with the development, inventory, sales, and marketing of any product (\"Products\") which EHS or EHN sells. 2.2 EHS: During any Services Term (defined below), Dr. Murray shall provide the following ongoing services to EHS for the compensation set forth in Article 5: (a) Provide guidance and/or lead initiatives related to the development of pharmaceutical forms of the EHS cannabinoid portfolio including methods to enhance bioavailability or delivery of these compounds. (b) Provide guidance and/or lead initiatives related to the scientific or clinical validation of the pharmaceutical forms of the EHS cannabinoid portfolio. (c) Provide such other services related to the foregoing as EHS may reasonably request from time to time. 2.3 EHN: During any Services Term (defined below), Dr. Murray shall provide the following ongoing services to EHN for the compensation set forth in Article 5: (a) Provide advice and general assistance in EHN's business efforts primarily involving product development, but also including guidance on marketing, sales, and product education. (b) Dr. Murray will act as public and private advocate for EHN at appropriate opportunities, including mutually agreed upon EHN educational events, public relations opportunities, and marketing efforts. (c) Provide such other services related to the foregoing as EHN may reasonably request from time to time.\n\nARTICLE 3 -- DEFINITION OF SCOPE 3.1 Licensing rights. EHS and EHN agree that they shall not use Dr. Murray's name or likeness on its products or product marketing materials unless specifically approved by Dr. Murray by written acknowledgement including emails and facsimile transmissions of his approval. 3.2 Exclusivity. Dr. Murray shall not directly assist in the development of any product competitive to products developed by EHS or EHN. 3.3 Additional Services. Compensation for any other mutually agreed upon project that is outside the scope of this Agreement will be negotiated and mutually agreed upon by the parties.\n\nARTICLE 4 -- PROPERTY RIGHTS 4.1 EHS and EHN shall have the exclusive rights in and to all ingredients, product specifications, goodwill, and all other intellectual property rights associated with any Product(s); provided, however, that EHS and EHN shall not have any rights in or to Dr. Murray's name or likeness except as expressly granted in writing herein or via electronic transmission by Dr. Murray. Neither shall Dr. Murray have any rights or interest whatsoever in any intellectual property, trademarks, trade names, service marks, or other names or marks owned or used by EHS.\n\n1\n\nSource: EMERALD HEALTH BIOCEUTICALS INC., 1-A, 2/18/2020\n\n\n\n\n\nARTICLE 5 -- COMPENSATION 5.1 Payment for Services. EHN will pay Dr. Murray $8,333 per month at the end of each month during the first twelve months that this agreement is in effect. 5.2 Options. Upon execution of this Agreement and on each anniversary date of this Agreement for as long as this Agreement is active, EHS will grant Dr. Murray options to purchase 25,000 shares of EHS common stock at their then fair market value (the \"Options\"). The Options will vest immediately on the date of grant. 5.3 Royalty/Commission Payments. Dr. Murray will receive an annual royalty on net sales (defined as gross sales minus returns) for any products (the \"Dr. Murray Products\") developed by Dr. Murray for EHN for as long as the Dr. Murray Products are being sold. The Dr. Murray Products will be listed on Schedule A attached hereto as they are developed and added to product portfolio. During each year of this agreement, Dr. Murray will be paid no later than the 30st day of January based on the cumulative Net Sales of the Dr. Murray Products for the preceding 12 months based upon the following scale:\n\nNet Sales per 12 Months Royalty $2,000,001 to $3,500,000 $150,000 $3,500,001 to $5,000,000 $250,000 $5,000,001 to $10,000,000 $350,000 $10,000,001 to $25,000,000 $500,000 $25,000,001 to $50,000,000 $1,000,000 $50,000,001 to $75,000,000 $1,500,000 $75,000,001 to $100,000,000 $2,000,000 Greater than $100,000,000 $2,500,000\n\n5.4 Ownership in EHN. Upon execution of this agreement, EHN will issue to Dr. Murray sufficient shares to represent a 5% equity ownership in EHN. 5.5 Expenses and Travel. Any pre-approved expenses incurred by Dr. Murray on behalf of EHS or EHN during any Services Term will be reimbursed, including but not limited to travel expenses incurred for air travel, car rental, hotels and meals, subject to prior approval in each case. EHS or EHN agrees to reimburse Dr. Murray for all reasonable expenses (air travel, hotel, car rental, meals, materials, etc.) relating to EHS or EHN directed activities, subject to prior approval in each case. 5.6 Withholdings and Taxes. Dr. Murray shall be responsible for all federal or state withholdings and taxes, and shall indemnify EHS or EHN for any actions brought against EHS or EHN with respect thereto. 5.7 Instructions for Payment. All payments due and payable to Dr. Murray hereunder shall be paid to:\n\nMichael T. Murray, N.D. [intentionally omitted] Or via electronic transfer as directed by Dr. Murray\n\n2\n\nSource: EMERALD HEALTH BIOCEUTICALS INC., 1-A, 2/18/2020\n\n\n\n\n\n5.8. EHS or EHN Benefits. Dr. Murray and Dr. Murray acknowledge and agree and it is the intent of the parties hereto that except as set forth in Section 5, neither Dr. Murray nor any employees or contractors of Dr. Murray receive any EHS-sponsored benefits, either as a consultant or employee. Such benefits include, but are not limited to, paid vacation, sick leave, medical insurance, and 401(k) participation.\n\nARTICLE 6 - TERM and TERMINATION of AGREEMENT 6.1 Term. This Agreement shall become effective as of the Effective Date and shall remain in effect as follows. (a) Dr. Murray's obligations set out herein shall be performed from the Effective Date until December 31, 2018 (the initial \"Services Term\"). The Services Term of this Agreement shall be automatically renewed for successive two-year terms thereafter unless written notice is given by either party to the other, indicating that party's intention not to renew the Services Term of this Agreement, at least ninety (90) days prior to the end of the initial Services Term or any renewed Services Term. (b) Except as otherwise stated herein as pertaining only to a Services Term, this Agreement shall remain in effect for ten years, unless terminated in accordance with Sections 6.1 (a) or 6.2(b). For the avoidance of doubt, it is the intent of the parties that subject to the terms and conditions set forth herein, the royalty payments set out above shall continue in perpetuity for as long as the Dr. Murray Products are being sold. 6.2 Termination EHS or EHN, on the one hand, and Dr. Murray, on the other, may terminate any Services Term of this Agreement by delivering 60 days written notice to the other party. Notwithstanding the foregoing, EHS or EHN may immediately terminate the Services Term without notice should Dr. Murray be in breach of this Agreement. 6.3 Effect of Termination. (a) If a Services Term is terminated or expires but this Agreement is not otherwise terminated in accordance with Section 6.2, all other rights and obligations shall remain in effect following the termination or expiration of the Services Term. These include without limitation Sections 2.1, 3.1, 3.2, 4.1, 5.2, 5.3, 7, 8 and 9. (b) If this Agreement is termination in accordance with Section 6.2 by Dr. Murray, all of the rights and obligations hereunder shall cease and be of no further force or effect, except that Sections 4, 5 (to the extent obligations have accrued prior to termination), 7, 8 and 9 shall survive. (c) If this Agreement is termination in accordance with Section 6.2 by EHS or EHN, all of the rights and obligations hereunder shall cease and be of no further force or effect, except that Sections 2.1, 3.1, 3.2, 4.1, 5.3, 7, 8 and 9 shall survive.\n\nARTICLE 7 -CONFIDENTIAL INFORMATION Neither EHS, EHN nor Dr. Murray shall disclose to any third parties, except as required by law, at any time during or subsequent to the term of this Agreement, any Confidential Information. \"Confidential Information: includes proprietary information, technical data, trade secrets or know-how, including, but not limited to, the terms and conditions of this Agreement, research, product plans, products, services, suppliers, customer lists and customers, prices and costs, markets, inventions, technology, formulas, specifications, designs, drawings, marketing, licenses, finances, budgets and other business information. Confidential information does not include information that (i) is or becomes generally known to the public, through no wrongful act of the receiving party; (ii) is lawfully obtained by the receiving party from a third party which has no obligation to maintain the information as confidential; (iii) was known prior to its disclosure to the receiving party without any obligation to keep it confidential as evidenced by tangible records kept by the receiving party\n\n3\n\nSource: EMERALD HEALTH BIOCEUTICALS INC., 1-A, 2/18/2020\n\n\n\n\n\nin the ordinary course of its business; (iv) is independently developed by the receiving party without reference to the disclosing party's Confidential Information; or (v) is the subject of a written agreement whereby the disclosing party consents to the use or disclosure of such Confidential Information. If the disclosure of any such confidential information by EHS or Dr. Murray to any third party is required in order to carry out the purpose and intent of this Agreement, then EHS and Dr. Murray shall cause such third party to enter into a non-disclosure Agreement with EHS and/or Dr. Murray as a condition to such disclosure.\n\nARTICLE 8 -- NOTICES All notices, communications, payments or other correspondence required to be given or made under this Agreement shall be in writing and shall be deemed received (a) on the same day if delivered in person, courier service, confirmed e-mail delivery, or facsimile transmission, (b) on the next day if delivered by next day Federal Express, UPS, or other reputable overnight carrier, or (c) within three (3) days if delivered by mail. All notices shall be given to the parties at the following addresses, or such other addresses as may be the subject of a notice given hereunder:\n\nEmerald Health Sciences Inc. Dr. Avtar Dhillon ad@dhillon.com\n\nEmerald Health Nutraceuticals Inc. Dr. Gaetano Morello gm@emerald.life\n\nMichael T. Murray, N.D. 8305 N. Ridgeview Drive Paradise Valley, AZ 85253 (480) 659-6733 Fax (480) 659-6753\n\nARTICLE 9 - GENERAL LEGAL MATTERS (1) Governing Law, Venue, Amendments and Merger: This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Arizona without regard to conflict of law principles, may not be amended except by a writing signed by both parties, and shall supersede any and all prior discussions and writings between the parties concerning the subject matter. The parties hereby unconditionally consent to the federal courts located in Arizona as the venue in any action arising out of or relating to this Agreement.\n\n(2) Waiver: No waiver by either party of a right on any one occasion shall constitute a waiver of such right on another occasion, and all such claimed waivers must be in writing signed by the party against whom the waiver is claimed.\n\n(3) Enforceability of Clauses: If any provision of this Agreement violates any law or is unenforceable for any other reason, it shall be severed from this Agreement without affecting the rest of the Agreement.\n\n(4) Consent Required: Neither party is the agent or franchisee of the other party, and neither party, under any circumstances, may bind the other party to any agreement or obligation to any third person without the written consent of the party being bound.\n\n4\n\nSource: EMERALD HEALTH BIOCEUTICALS INC., 1-A, 2/18/2020\n\n\n\n\n\nIn all matters relating to thisAgreement, both parties shall be acting solely as independent contractors and shall be solely responsible for the acts of their respective employees, contractors and agents. Employees, agents and contractors of one party shall not be considered employees, agents or contractors of the other party. Any consent or approval by a party to this Agreement shall be made only by a duly authorized officer of that party.\n\n(5) Warranty of Authority: Each party represents and warrants that it has the full right and authority to enter into this Agreement without violating the rights of any third party or violating any applicable law or court order.\n\n(6) Disputes: The parties shall first attempt to resolve any dispute related to this Agreement in an amicable manner by mediation conducted in Phoenix, Arizona. The mediation shall take place no more than sixty (60) days after written notice from the party requesting such mediation. Any disputes remaining unresolved after mediation shall be settled by binding arbitration conducted in Phoenix, Arizona under the Commercial Arbitration Rules of the American Arbitration Association (AAA). Notwithstanding the foregoing, (i) the AAA shall not mediate or arbitrate the dispute, and the parties shall agree upon a mediator and arbitrator, if necessary, but if the parties cannot agree upon such mediator or arbitrator, Judicial Dispute Resolution of Phoenix, AZ shall select one of its mediators/arbitrators to serve pursuant to this Agreement, and (ii) either party may apply to any court of competent jurisdiction in Maricopa County, Arizona for such equitable, extraordinary or injunctive relief as may be necessary to enforce the respective rights of the parties under this Agreement. The prevailing party in arbitration or litigation shall be entitled to recover its costs and reasonable attorney's fees and expenses, as determined by the arbitrator or judge, as applicable.\n\n(7) Entire Agreement: This Agreement contains the entire agreement of the parties.\n\n(8) Force Majeure: A party shall not be responsible for any failure to timely perform due to a \"Force Majeure\" event, which is an event that is beyond the reasonable control of a party and not reasonably foreseeable with the exercise of reasonable care, nor avoidable through the payment of nonmaterial additional sums (nor due the negligence, inattention, misconduct or inexperience of the affected party). In such event, the party affected shall give prompt written notice to the other party of the cause and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as possible.\n\n(9) Counterparts: This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall be deemed to constitute one instrument.\n\n(10) Electronic Means: Delivery of an executed copy of this Agreement by electronic facsimile transmission or other means of electronic communication capable of providing a printed copy will be deemed to be execution and delivery of this Agreement as of the Effective Date. A confirming copy of the same shall be sent by mail to the above address\n\n(11) Assignment: Dr. Murray has unique qualifications to provide the services contemplated herein, and shall not assign any of its or his rights or obligations to any other person or entity without EHS's written consent, which may be withheld or granted in EHS's discretion.\n\nIn witness whereof the parties have caused this Agreement to be executed and delivered by their respective duly authorized representatives as of the Effective Date.\n\n5\n\nSource: EMERALD HEALTH BIOCEUTICALS INC., 1-A, 2/18/2020\n\n\n\n\n\nDr. Murray Emerald Health Sciences Inc.\n\n/s/Michael T. Murray, N.D By:/s/ Avtar Dhillon Michael T. Murray, N.D\n\nEmerald Health Nutraceuticals Inc. By:/s/Gaetano Morello\n\n1\n\nSource: EMERALD HEALTH BIOCEUTICALS INC., 1-A, 2/18/2020"
  }
]